Home » Posts tagged with » Switzerland
Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies

Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies

Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B virus (HBV) infection using its GalXC RNAi platform technology. The collaboration between the Dicerna Pharmaceuticals and the Swiss drugmaker will focus on the global development and commercialization of the former’s […]

Galderma launches phase 3 atopic dermatitis trial for nemolizumab

Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the treatment of moderate-to-severe atopic dermatitis. The late-stage clinical trial will feature adult patients, who are randomly grouped in a double-blinded, placebo-controlled study that will assess the efficacy and safety of the […]

Continue reading …
RESTORE clinical trial of STR001 : Strekin completes patient enrollment

RESTORE clinical trial of STR001 : Swiss biopharma company Strekin has wrapped up patient enrollment in a phase 3 study, called RESTORE, for evaluating its small molecule STR001 in patients after a sudden sensorineural hearing loss (SSNHL) event. The late-stage trial is a global, randomized, placebo-controlled study, which will feature 165 patients at nearly 25 […]

Continue reading …
Gilead Sciences licenses three preclinical antiviral programs from Novartis

US biopharma company Gilead Sciences has licensed three preclinical antiviral programs, including investigational candidates having the potential to treat human rhinovirus, influenza and herpes viruses, from Swiss pharma company Novartis. As per the agreement, Gilead Sciences will get exclusive global rights for the development and commercialization of small molecules against three undisclosed targets. Novartis will […]

Continue reading …
Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics

Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as per the latest pharma acquisition news. AMAL Therapeutics, which was spun out from the University of Geneva in 2012, is focused on cancer immunotherapy and is engaged in advancing therapeutic […]

Continue reading …
Pfizer wraps up $810m acquisition of Swiss biotech company Therachon

Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech company Therachon, which is focused on rare diseases, in a deal worth up to $810 million, as per the latest pharma acquisition news. The clinical-stage Therachon is currently engaged in developing treatment of achondroplasia and short bowel […]

Continue reading …
Merck to invest €150m to expand Aubonne biotech manufacturing site

Pharma giant Merck revealed its plans to invest €150 million in its Aubonne biotech manufacturing site in Switzerland to expand manufacturing capacity for its biotech medicines. The investment, which will be between 2019 and 2023, will be made on the construction of a new building dedicated to manufacturing the company’s biotech medicines to be supplied […]

Continue reading …
Orphan Technologies begins OT-58 phase 1/2 trial in classical homocystinuria

OT-58 clinical trial news : Swiss pharma company Orphan Technologies has dosed the first patients in a phase 1/2 trial, called CBS-HCY-01, of its modified recombinant enzyme therapy OT-58 in classical homocystinuria. OT-58 has been designed to dramatically reduce tissue and plasma levels of homocysteine, thereby potentially preventing, delaying, and reversing clinical abnormalities, and lifting […]

Continue reading …
Novartis to acquire US biopharma company Endocyte for $2.1bn

Swiss pharma giant Novartis has signed a deal valued at about $2.1 billion to acquire US biopharma company Endocyte in a move to expand its expertise in radiopharmaceuticals for the treatment of cancer. According to the merger terms, the Swiss pharma giant will buy all the shares of Endocyte at $24 per share. The US […]

Continue reading …
Roivant launches Respivant Sciences to develop drugs for respiratory diseases

Roivant Sciences has launched a new biopharma company named Respivant Sciences which will focus on developing innovative therapeutics for serious respiratory diseases. The new biopharma company of Roivant Sciences will be headed by Bill Gerhart – CEO, Ahmet Tutuncu – Executive Vice President for Clinical and Regulatory, and Pravin Soni – Executive Vice President for […]

Continue reading …
Page 1 of 212